 Shares of OpGen NASDAQ:OPGN rose 4.98 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 226.67 over the past year to 0.49, which beat the estimate of 0.51.Revenue of 1,188,000 up by 17.62 from the same period last year, which missed the estimate of 1,200,000.Outlook Earnings guidance hasnt been issued by the company for now.OpGen hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 12, 2020View more earnings on OPGNTime: 04:30 PMET Webcast URL: Companys 52-week high was at 12.8052-week low: 0.24Price action over last quarter: Up 25.00Company Profile OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The companys product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledgebase.See more from Benzinga Earnings Scheduled For August 12, 2020 A Preview Of OpGens EarningsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 